The DOI matches its Crossref record.
Effect of bupropion-SR on REM sleep: relationship to antidepressant response
Abstract
Rationale The effects of antidepressant (AD) drugs on sleep in depressed patients and their relationship to AD response have been investigated previously. However, newer AD agents, which appear to have different effects on sleep, have not been evaluated systematically for their usefulness in predicting treatment response. Objectives To examine the effect of bupropion sustained release (SR) (Wellbutrin SR) on sleep macroarchitecture, and to assess whether the observed electroencephalographic (EEG) sleep changes in response to a single dose of bupropion are associated with treatment response to the AD. Methods Twenty patients with unipolar major depressive disorder received EEG sleep assessments prior to treatment. Subjects were studied twice for 2 consecutive nights, with each 2-night session approximately 1 week apart. Baseline EEG sleep and the EEG sleep responses to placebo (baseline sleep) and a single dose of bupropion SR (150 mg, PO) were measured using a randomized, double-blind, crossover design. The participants then received open-label treatment with bupropion SR for about 8 weeks. Results No relationship was observed between baseline EEG sleep measures and response to treatment with bupropion. However, a statistically significant relationship was found between latency to the onset of rapid eye movement (REM) sleep following a single dose of bupropion and clinical response to treatment with bupropion. Responders showed an increase in REM latency following bupropion c…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In depressed patients, treatment response to bupropion was associated with significant REM suppression.
“(Ott et al., 2002) found no differences with regard to sleep measures between bupoprion (150400mg) and placebo, although treatment response was associated with significant REM suppression.”
From Antidepressants and their effect on sleep (2005) · cites this paper as Ott et al., 2002
In depressed patients, bupropion 150-400 mg did not differ from placebo on sleep measures.
“(Ott et al., 2002) found no differences with regard to sleep measures between bupoprion (150400mg) and placebo, although treatment response was associated with significant REM suppression.”
From Antidepressants and their effect on sleep (2005) · cites this paper as Ott et al., 2002
Citations
Cited by
Sorted by citations
Comorbidity of insomnia and depression
Staner, L. (2010) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2009.09.003 · Cited by 481
Antidepressants and their effect on sleep
Mayers, A. G., & Baldwin, D. S. (2005) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.726 · Cited by 323
Circadian rhythms and depression: Human psychopathology and animal models
Kronfeld-Schor, N., & Einat, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.020 · Cited by 166
Omega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients With Major Depressive Disorder
Gertsik, L., Poland, R. E., Bresee, C., & Rapaport, M. H. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823f3b5f · Cited by 162
Self-citationBupropion-Induced Sleepwalking
Oulis, P., Kokras, N., Papadimitriou, G. N., & Masdrakis, V. G. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c9c8a2 · Cited by 22
Metadata
- Authors
- Ott, G., Rao, U., Nuccio, I., Lin, K.-M., & Poland, R.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Poland, Russell
- Venue
- Psychopharmacology
- Published
- 2002-12-01
- Volume
- 165
- Issue
- 1
- Pages
- 29-36
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2044865959
- Cited by
- 34
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 1 · 2022: 2 · 2021: 3 · 2019: 1 · 2015: 1 · 2014: 1 · 2013: 1
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (R01MH062464, T32MH018825, K08MH001419, MH-34471, R01MH047193)
- National Institute on Drug Abuse (R01DA014037)
- National Center for Research Resources (M01RR000425)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Keywords
- bupropion sustained release, REM latency, antidepressant response prediction, major depressive disorder, dopamine D2 receptor, noradrenergic mechanisms, treatment response
- MeSH terms
- Adult, Depressive Disorder, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Reaction Time, Sleep, REM, Bupropion, Polysomnography, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
